Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
62332-0620-05 62332-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0621-17 62332-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0622-50 62332-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0620-05 46708-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0621-17 46708-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0622-50 46708-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
00310-4535-30 00310-4535 Tremelimumab IMJUDO 300.0 mg/15mL Immunotherapy Monoclonal Antibody CTLA-4 Intravenous Oct. 21, 2022 In Use
00310-4505-25 00310-4505 Tremelimumab IMJUDO 25.0 mg/1.25mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Oct. 21, 2022 In Use
69339-0171-03 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0171-05 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-03 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-05 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
71335-2181-01 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-02 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-03 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
51655-0933-04 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 25, 2022 In Use
00615-8440-05 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
00615-8440-39 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
69238-2122-09 69238-2122 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
51655-0008-20 51655-0008 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 31, 2022 In Use
70518-2138-04 70518-2138 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 31, 2022 In Use
00615-8438-39 00615-8438 PREDNISONE Prednisone 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 1, 2022 In Use
43598-0171-11 43598-0171 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Nov. 1, 2022 In Use

Found 10,000 results in 5 milliseconds — Export these results